Publications in collaboration with researchers from Hospital Universitario Virgen del Rocío (31)

2022

  1. Withdrawal of dacomitinib treatment due to absence of toxicities is not justified

    Future Oncology

2021

  1. The patient's perspective on treatment with dacomitinib: Patient-reported outcomes from the Phase III trial ARCHER 1050

    Future Oncology, Vol. 17, Núm. 7, pp. 783-794

  2. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    Drugs, Vol. 81, Núm. 2, pp. 257-266

2020

  1. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

    Lung Cancer, Vol. 147, pp. 137-142

  2. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

    European Journal of Cancer, Vol. 141, pp. 193-198

  3. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

    Journal of Thoracic Oncology

2019

  1. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108

2018

  1. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations

    Journal of Clinical Oncology, Vol. 36, Núm. 22, pp. 2244-2250

  2. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

    European Respiratory Journal

2017

  1. Carcinoma epidermoide primario de tiroides. Valoración inicial y control evolutivo mediante 18F-FDG PET/TC

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 36, Núm. 4, pp. 257-259

  2. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 11, pp. 1454-1466

  3. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

    Investigational New Drugs, Vol. 35, Núm. 2, pp. 198-206

  4. Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1590-1596

  5. Second-Line Treatment Selection in Patients With Non–Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians

    Clinical Lung Cancer, Vol. 18, Núm. 2, pp. e89-e97

2016

  1. 180P: Immunotherapy as an effective therapy approach for advanced non-small cell lung cancer (NSCLC): A single institution experience in the context of clinical trials and expanded access use

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S135-S136

  2. 183P: Second-line treatment selection in patients with non-small cell lung cancer of adenocarcinoma histology: A European survey

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S137

  3. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

    ESMO Open, Vol. 1, Núm. 6

2015

  1. Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies

    Cancer Treatment Reviews, Vol. 41, Núm. 1, pp. 27-34

  2. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1020-1029

2014

  1. Treatment for early-stage lung cancer: What next?

    The Lancet